0

Insulin Drugs Global Market Report 2020

Region:Global

Author(s):

Product Code:7264

Download Sample Report download
Buy the Full ReportStarting from $4000
Published on

February 2020

Total pages

200

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $4000

About the Report

About the Report

The insulin drugs market consists of manufacturers' sales of insulin drugs and types of Insulin by entities (organizations, sole traders and partnerships) which are used to treat diabetes. Insulin is a medication prescribed to treat type 1 diabetes and type 2 diabetes mellitus. There are several types, preparations, and dosage amounts of insulin. Insulin is a hormone that is produced naturally in our bodies. Its main role is to allow cells throughout the body to uptake glucose (sugar) and convert it into a form that can be used by these cells for energy. The market covered in this report does not include non insulin drugs and other antidiabetic drugs or medicine.
 
The global insulin drugs market was valued at about USD 25.44 billion in 2019 and is expected to grow to USD 29.39 billion at a CAGR of 7% through 2023.
 
The insulin drugs market has been geographically segmented into North America, Western Europe, Asia-Pacific, Eastern Europe, South America and Middle East & Africa. The North American market is the largest market for insulin drugs and is expected to continue to be the largest market during the forecast period.
 
The insulin drugs market covered in this report is segmented by product type into basal or long acting insulins, bolus or fast-acting insulins, traditional human insulins, combination insulins, biosimilar insulins. It is also segmented by application into type II diabetes, type I diabetes, gestational diabetes, prediabetes.
 
Changing lifestyles are leading to a higher prevalence of diabetes. This is expected to drive the demand for diabetes drugs during the forecast period. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of diabetes. According to a study conducted in 2018, there was a high prevalence of diabetes in people with sedentary lifestyles. Additionally, people suffering from obesity are up to 80 times more likely to develop type 2 diabetes. According to a World Health Organization (WHO) report, 74% of men and 64% of women in the UK, for instance, are expected to be overweight by 2030. These factors are expected to increase the patient pool of diabetes, thereby likely to drive the diabetes therapies market during the forecast period.
 
High costs and long payback periods for investment in new diabetes drugs negatively impacted the market during the historic period. The costs for drug approval processes that include multiple phases of clinical trials and screening processes with regulatory bodies such as the US FDA are very high. According to the Tufts Center for the Study of Drug Development, the cost of bringing a new drug from its conception to shelves was about USD 2.7 billion in 2017, a significant increase from USD 320 million in the 1990s. These high costs and uncertainty regarding return on investments for drug development limited the investments by pharmaceutical companies in the development of new diabetic drugs, thus limiting the growth of the market during the historic period.
 
There is an increased trend of mergers and acquisitions for the new formulations in Insulin market and the companies are investing in development of new medicines in Insulin drugs market. For example, in December 2016, researchers at Lund University Diabetes Centre in Sweden, worked on CRISPR, a genome modification tool. This resulted in turning off of one of the genes which was responsible for causing diabetes. This effectively decreased beta cell death and increased insulin production in the pancreas. Insulin maker, Novo Nordisk has developed a diabetes pill and it is expected to be launched in 2020. This pill belongs to a blockbuster class of drugs, glucagon like peptide-1 (GLP-1s) that stimulate insulin production. The new drug is expected to generate about USD 5 billion in annual sales.
 
In August 2018, Novo Nordisk acquired Ziylo which is a University of Bristol spin-out company for an undisclosed amount in the UK. Novo Nordisk has full rights to Ziylo's glucose binding molecule platform to develop glucose responsive insulins. This development is a key strategic area for Novo Nordisk and should result in more effective insulin therapy. Ziylo is a pharmaceutical Company that has developed Biomimetic Glucose Binding Molecules (GBM) for Continuous Glucose Monitors (CGM) & Glucose Responsive Insulins (GRI).
 
Major players in the market are Apidra, Eli Lilly, Humalog, Humulin, Insuman, Lantus, Levemir, Novo Nordisk, Novomix, NovoRapid/Novolog

Products

Products

1) By Product Type: Basal or Long Acting Insulins; Bolus or Fast-Acting Insulins; Traditional Human Insulins; Combination Insulins; Biosimilar Insulins 2) By Application: Type II Diabetes; Type I Diabetes; Gestational Diabetes; Prediabetes


Companies

Apidra

Eli Lilly

Humalog

Humulin

Insuman

Lantus

Levemir

Novo Nordisk

Novomix

NovoRapid/Novolog

Actrapid

Admelog

Novolin/Actrapid/Insulatard

Ryzodeg

Sanofi

Soliqua/Suliqua

Toujeo

Tresiba

Xultophy

Table of Contents

Table of Contents

1. Executive Summary

2. Insulin Drugs Market Characteristics

3. Insulin Drugs Market Size And Growth

3.1. Global Insulin Drugs Historic Market, 2015-2019, USD Billion

3.1.1. Drivers Of The Market

3.1.2. Restraints On The Market

3.2. Global Insulin Drugs Forecast Market, 2019-2023F, 2025F, 2030F, USD Billion

3.2.1. Drivers Of The Market

3.2.2. Restraints On the Market

4. Insulin Drugs Market Segmentation

4.1. Global Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Basal or Long Acting Insulins

Bolus or Fast-Acting Insulins

Traditional Human Insulins

Combination Insulins

Biosimilar Insulins

4.2. Global Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Type II Diabetes

Type I Diabetes

Gestational Diabetes

Prediabetes

5. Insulin Drugs Market Regional And Country Analysis

5.1. Global Insulin Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

5.2. Global Insulin Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

6. Asia-Pacific Insulin Drugs Market

6.1. Asia-Pacific Insulin Drugs Market Overview

6.2. Asia-Pacific Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

7. China Insulin Drugs Market

7.1. China Insulin Drugs Market Overview

7.2. China Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,USD Billion

8. India Insulin Drugs Market

8.1. India Insulin Drugs Market Overview

8.2. India Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

9. Japan Insulin Drugs Market

9.1. Japan Insulin Drugs Market Overview

9.2. Japan Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

10. Australia Insulin Drugs Market

10.1. Australia Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

11. Indonesia Insulin Drugs Market

11.1. Indonesia Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

12. South Korea Insulin Drugs Market

12.1. South Korea Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

13. Western Europe Insulin Drugs Market

13.1. Western Europe Insulin Drugs Market Overview

13.2. Western Europe Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

14. UK Insulin Drugs Market

14.1. UK Insulin Drugs Market Overview

14.2. UK Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

15. Germany Insulin Drugs Market

15.1. Germany Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

16. France Insulin Drugs Market

16.3. France Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

17. Eastern Europe Insulin Drugs Market

17.1. Eastern Europe Insulin Drugs Market Overview

17.2. Eastern Europe Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

18. Russia Insulin Drugs Market

18.1. Russia Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

19. North America Insulin Drugs Market

19.1. North America Insulin Drugs Market Overview

19.2. North America Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

20. USA Insulin Drugs Market

20.1. USA Insulin Drugs Market Overview

20.2. USA Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

21. South America Insulin Drugs Market

21.1. South America Insulin Drugs Market Overview

21.2. South America Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

22. Brazil Insulin Drugs Market

22.1. Brazil Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

23. Middle East Insulin Drugs Market

23.1. Middle East Insulin Drugs Market Overview

23.2. Middle East Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

24. Africa Insulin Drugs Market

24.1. Africa Insulin Drugs Market Overview

24.2. Africa Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

25. Insulin Drugs Market Competitive Landscape And Company Profiles

25.1. Insulin Drugs Market Competitive Landscape

25.2. Insulin Drugs Market Company Profiles

25.2.1. Apidra

25.2.1.1. Overview

25.2.1.2. Products and Services

25.2.1.3. Strategy

25.2.1.4. Financial Performance

25.2.2. Eli Lilly

25.2.2.1. Overview

25.2.2.2. Products and Services

25.2.2.3. Strategy

25.2.2.4. Financial Performance

25.2.3. Humalog

25.2.3.1. Overview

25.2.3.2. Products and Services

25.2.3.3. Strategy

25.2.3.4. Financial Performance

25.2.4. Humulin

25.2.4.1. Overview

25.2.4.2. Products and Services

25.2.4.3. Strategy

25.2.4.4. Financial Performance

25.2.5. Insuman

25.2.5.1. Overview

25.2.5.2. Products and Services

25.2.5.3. Strategy

25.2.5.4. Financial Performance

26. Key Mergers And Acquisitions In The Insulin Drugs Market

27. Insulin Drugs Market Trends And Strategies

28. Insulin Drugs Market Future Outlook and Potential Analysis

29. Appendix

29.1. Abbreviations

29.2. Currencies

29.3. Research Inquiries

29.4. The Business Research Company

29.5. Copyright And Disclaimer

 


List of Figure

Figure 1: Global Historic Market Growth, 2015-2019, USD Billion

Figure 2: Global Forecast Market Growth, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 3: Global Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 4: Global Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 5: Global Insulin Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 6: Global Insulin Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 7: Asia-Pacific, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 8: China, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 9: India, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 10: Japan, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 11: Australia, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 12: Indonesia, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 13: South Korea, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 14: Western Europe, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 15: UK, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 16: Germany, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 17: France, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 18: Eastern Europe, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 19: Russia, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 20: North America, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 21: USA, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 22: South America, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 23: Brazil, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 24: Middle East, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 25: Africa, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Figure 26: Apidra Financial Performance

Figure 27: Eli Lilly Financial Performance

Figure 28: Humalog Financial Performance

Figure 29: Humulin Financial Performance

Figure 30: Insuman Financial Performance


List of Table

Table 1: Global Historic Market Growth, 2015-2019, USD Billion

Table 2: Global Forecast Market Growth, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 3: Global Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 4: Global Insulin Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 5: Global Insulin Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 6: Global Insulin Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 7: Asia-Pacific, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 8: China, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 9: India, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 10: Japan, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 11: Australia, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 12: Indonesia, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 13: South Korea, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 14: Western Europe, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 15: UK, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 16: Germany, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 17: France, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 18: Eastern Europe, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 19: Russia, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 20: North America, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 21: USA, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 22: South America, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 23: Brazil, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 24: Middle East, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 25: Africa, Insulin Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, USD Billion

Table 26: Apidra Financial Performance

Table 27: Eli Lilly Financial Performance

Table 28: Humalog Financial Performance

Table 29: Humulin Financial Performance

Table 30: Insuman Financial Performance

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022